Notice of Acceptance marks first Australian patent covering Anixa's breast cancer vaccine platform

Continues expansion of global intellectual property coverage in markets with increasing breast cancer incidence rates

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, announced that IP Australia has issued a Notice of Acceptance for a new patent related to Anixa's breast cancer vaccine technology.

This patent, exclusively licensed from Cleveland Clinic, will provide protection for the Company's novel approach to breast cancer treatment and prevention in Australia. The patent is titled, "Vaccine Adjuvants and Formulations," and the co-inventors are Dr. Justin Johnson and the late Dr. Vincent Tuohy, both of Cleveland Clinic.

The acceptance further expands the international scope of Anixa's intellectual property portfolio, reinforcing its leadership in the field of cancer immunotherapy. The Australian patent complements patents issued in the United States and other key global jurisdictions, including Europe, China, and Japan, among others, and represents an important step toward potential future regulatory approvals and commercialization efforts outside the United States.

In a recently completed Phase 1 trial, at Cleveland Clinic and funded by the U.S. Department of Defense, the vaccine met all major primary endpoints, was safe and well tolerated, and generated protocol defined immune responses in more than 74% of participants. These results support continued clinical development of the Company's novel preventive and therapeutic breast cancer vaccine.

"This newly accepted patent continues the broad international recognition of the novelty and potential of our breast cancer vaccine," stated Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences. "As we continue clinical development in the U.S., our growing international patent estate further strengthens our ability to pursue global opportunities and potentially partner with larger pharmaceutical companies for worldwide commercialization."

Breast cancer remains the most commonly diagnosed cancer among women worldwide, and while survival rates in Australia remain high, incidence rates have continued to increase. Despite significant advances in screening and treatment, there are currently no approved vaccines designed to prevent breast cancer.

Anixa's breast cancer vaccine is based on immunizing against human α-lactalbumin, a protein associated with lactation that is aberrantly expressed in certain types of breast cancer. This "retired" protein strategy, developed at Cleveland Clinic and licensed exclusively to Anixa, aims to selectively prime the immune system to prevent tumor formation while avoiding harm to normal tissue, particularly in aggressive forms of the disease such as triple-negative breast cancer.

By reinforcing its global patent estate, Anixa is laying the groundwork for future international development and commercialization strategies. The Company's broader vaccine platform also targets other high-incidence cancers and is designed to transform how the medical community approaches cancer prevention. If successful, the technology could represent one of the first preventive vaccine approaches targeting breast cancer.